Identification

Name
Gabexate
Accession Number
DB12831
Type
Small Molecule
Groups
Investigational
Description

Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis [4] [5] [6].

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Gabexate mesylateE3Q07L064956974-61-9DNTNDFLIKUKKOC-UHFFFAOYSA-N
Categories
UNII
4V7M9137X9
CAS number
39492-01-8
Weight
Average: 321.377
Monoisotopic: 321.168856233
Chemical Formula
C16H23N3O4
InChI Key
YKGYIDJEEQRWQH-UHFFFAOYSA-N
InChI
InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)
IUPAC Name
ethyl 4-[(6-carbamimidamidohexanoyl)oxy]benzoate
SMILES
CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1

Pharmacology

Indication

No approved indication.

Structured Indications
Not Available
Pharmacodynamics

Gabexate bind and inhibits serine proteases in the coagulation cascade to prevent blood clotting [3]. It also prevents proteolytic destruction of IkappaB resulting in suppression of the nuclear factor kappa-B signalling pathway [1]. Ultimately this decreases the production of inflammatory cytokines such as tumor necrosis factor alpha which are produced as a result of NFkappaB activation.

Mechanism of action

Gabexate inhibits kallikrein, plasmin, and thrombin by binding to their active sites [2] [3]. The inhibition of these components of the coagulation cascade ultimately prevents the formation of fibrin which must be present and polymerized to form a clot. Gabexate decreases the production of inflammatory cytokines by attenuating NFkappaB and c-Jun N-terminal kinase (JNK) pathway activity [1]. The exact mechanism for this is unknown but it is thought that gabexate prevents the proteolyytic destruction of IkappaB which deactivates NFkappaB and interferes with activator protein 1 binding to DNA.

TargetActionsOrganism
APlasma kallikrein
inhibitor
Human
AProthrombin
inhibitor
Human
APlasminogen
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

LD50 of 6480mg/kg observed in rats [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Gabexate.Investigational
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Gabexate.Approved, Investigational
AbciximabAbciximab may increase the anticoagulant activities of Gabexate.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Gabexate.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Gabexate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Gabexate.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Gabexate.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Gabexate.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Gabexate.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Gabexate can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Gabexate.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Gabexate.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Gabexate.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Gabexate.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Gabexate.Approved
AltrenogestThe therapeutic efficacy of Gabexate can be decreased when used in combination with Altrenogest.Vet Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Gabexate.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Gabexate.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Gabexate.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Gabexate.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Gabexate.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Gabexate.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Gabexate.Approved
AncrodAncrod may increase the anticoagulant activities of Gabexate.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Gabexate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Gabexate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Gabexate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Gabexate.Approved, Investigational
Antithrombin III humanAntithrombin III human may increase the anticoagulant activities of Gabexate.Approved
ApixabanApixaban may increase the anticoagulant activities of Gabexate.Approved
ApocyninApocynin may increase the anticoagulant activities of Gabexate.Investigational
ApremilastApremilast may increase the anticoagulant activities of Gabexate.Approved, Investigational
ArdeparinArdeparin may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Gabexate.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Gabexate.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Gabexate.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Gabexate.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Gabexate.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Gabexate.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Gabexate.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Gabexate.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Gabexate.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Gabexate.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Gabexate.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Gabexate.Approved
BeraprostBeraprost may increase the anticoagulant activities of Gabexate.Investigational
BevoniumBevonium may increase the anticoagulant activities of Gabexate.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Gabexate.Approved, Investigational
BoceprevirThe serum concentration of Gabexate can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BrinaseBrinase may increase the anticoagulant activities of Gabexate.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Gabexate.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Gabexate.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Gabexate.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Gabexate.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Gabexate.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Gabexate.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Gabexate.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Gabexate.Approved
CangrelorCangrelor may increase the anticoagulant activities of Gabexate.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Gabexate.Investigational
CarbamazepineThe metabolism of Gabexate can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Gabexate.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Gabexate.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Gabexate.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Gabexate.Approved, Investigational
CertoparinCertoparin may increase the anticoagulant activities of Gabexate.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Gabexate.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Gabexate.Approved
CilostazolCilostazol may increase the anticoagulant activities of Gabexate.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Gabexate.Approved, Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Gabexate.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Gabexate.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Gabexate.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Gabexate.Approved
CloricromenCloricromen may increase the anticoagulant activities of Gabexate.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Gabexate.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Gabexate is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Gabexate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Gabexate.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Gabexate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Gabexate is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Gabexate.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Gabexate.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Gabexate.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Gabexate.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Gabexate.Approved, Withdrawn
DarexabanDarexaban may increase the anticoagulant activities of Gabexate.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Gabexate.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Gabexate is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Gabexate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Gabexate.Approved
DemegestoneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Gabexate is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Gabexate.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Gabexate.Approved, Investigational
DesirudinDesirudin may increase the anticoagulant activities of Gabexate.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Gabexate.Investigational
DesogestrelThe therapeutic efficacy of Gabexate can be decreased when used in combination with Desogestrel.Approved
DextranDextran may increase the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
Dextran 40Dextran 40 may increase the anticoagulant activities of Gabexate.Approved
Dextran 70Dextran 70 may increase the anticoagulant activities of Gabexate.Approved
Dextran 75Dextran 75 may increase the anticoagulant activities of Gabexate.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Gabexate.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Gabexate.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Gabexate.Approved, Investigational
DienogestThe therapeutic efficacy of Gabexate can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Gabexate.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Gabexate.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Gabexate.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Gabexate.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Gabexate.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Gabexate.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Gabexate.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Gabexate.Approved
DitazoleDitazole may increase the anticoagulant activities of Gabexate.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Gabexate.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Gabexate.Approved, Investigational
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Gabexate.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Gabexate.Investigational
DydrogesteroneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Gabexate.Approved
E-6201E-6201 may increase the anticoagulant activities of Gabexate.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Gabexate.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Gabexate.Approved, Investigational
EnoxaparinEnoxaparin may increase the anticoagulant activities of Gabexate.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Gabexate.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Gabexate.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Gabexate.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Gabexate.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Gabexate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Gabexate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Gabexate.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Gabexate.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Gabexate.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Gabexate.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Gabexate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Gabexate.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Gabexate.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Gabexate.Approved, Investigational
EstriolEstriol may decrease the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Gabexate.Approved
EstroneEstrone may decrease the anticoagulant activities of Gabexate.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Gabexate.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Gabexate.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Gabexate.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Gabexate.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Gabexate.Withdrawn
EtodolacEtodolac may increase the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Gabexate.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Gabexate can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Gabexate.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Gabexate.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Gabexate.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Gabexate.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Gabexate.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Gabexate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Gabexate.Approved
FentiazacFentiazac may increase the anticoagulant activities of Gabexate.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Gabexate.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Gabexate.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Gabexate.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Gabexate.Approved, Withdrawn
FluindioneGabexate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Gabexate.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Gabexate.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Gabexate.Approved, Investigational
FondaparinuxFondaparinux may increase the anticoagulant activities of Gabexate.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Gabexate.Approved, Investigational
GarlicThe serum concentration of Gabexate can be decreased when it is combined with Garlic.Approved
GenisteinGenistein may decrease the anticoagulant activities of Gabexate.Investigational
GestodeneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Gabexate.Experimental
HeminHemin may increase the anticoagulant activities of Gabexate.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Gabexate.Experimental
HeparinHeparin may increase the anticoagulant activities of Gabexate.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Gabexate.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Gabexate.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Gabexate.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Gabexate is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Gabexate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Gabexate.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Gabexate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Gabexate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Gabexate.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Gabexate.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Gabexate.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Gabexate.Investigational
IloprostIloprost may increase the anticoagulant activities of Gabexate.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Gabexate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Gabexate.Approved
IndobufenIndobufen may increase the anticoagulant activities of Gabexate.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Gabexate.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Gabexate.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Gabexate.Experimental
IsoxicamIsoxicam may increase the anticoagulant activities of Gabexate.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Gabexate.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Gabexate.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Gabexate.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Gabexate.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Gabexate.Approved
LetaxabanLetaxaban may increase the anticoagulant activities of Gabexate.Investigational
LevonorgestrelThe therapeutic efficacy of Gabexate can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Gabexate.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Gabexate.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Gabexate.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Gabexate.Experimental
LonazolacLonazolac may increase the anticoagulant activities of Gabexate.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Gabexate.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Gabexate.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Gabexate.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Gabexate.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Gabexate.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Gabexate.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Gabexate.Approved
Megestrol acetateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranGabexate may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Gabexate.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Gabexate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Gabexate.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Gabexate.Approved
MethylestrenoloneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Methylestrenolone.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Gabexate.Approved, Illicit
MilrinoneMilrinone may increase the anticoagulant activities of Gabexate.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Gabexate.Approved
MizoribineMizoribine may increase the anticoagulant activities of Gabexate.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Gabexate.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Gabexate.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Gabexate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Gabexate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Gabexate.Approved
NadroparinNadroparin may increase the anticoagulant activities of Gabexate.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Gabexate.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Gabexate.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Gabexate.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Gabexate.Approved, Withdrawn
NepafenacNepafenac may increase the anticoagulant activities of Gabexate.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Gabexate.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Gabexate.Approved
NimesulideNimesulide may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Gabexate is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Gabexate.Investigational
NomegestrolThe therapeutic efficacy of Gabexate can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Gabexate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Gabexate is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Gabexate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Gabexate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Gabexate is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Gabexate.Approved, Nutraceutical
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Gabexate.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Gabexate.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Gabexate.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Gabexate.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Gabexate.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Gabexate.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Gabexate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Gabexate.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Gabexate.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Gabexate.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Gabexate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Gabexate.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Gabexate is combined with Pethidine.Approved
PhenindionePhenindione may increase the anticoagulant activities of Gabexate.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Gabexate.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Gabexate.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Gabexate.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Gabexate.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Gabexate.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Gabexate.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Gabexate.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Gabexate.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Gabexate.Approved
ProgesteroneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Gabexate.Experimental
PromegestoneThe therapeutic efficacy of Gabexate can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Gabexate.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Gabexate.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Gabexate.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Gabexate.Experimental
Protein CProtein C may increase the anticoagulant activities of Gabexate.Approved
Protein S humanGabexate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeProtocatechualdehyde may increase the anticoagulant activities of Gabexate.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Gabexate.Approved
PTC299PTC299 may increase the anticoagulant activities of Gabexate.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Gabexate.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Gabexate.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Gabexate.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Gabexate.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Gabexate.Approved, Investigational
ReviparinReviparin may increase the anticoagulant activities of Gabexate.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Gabexate.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Gabexate.Approved
RivaroxabanGabexate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Gabexate.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Gabexate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Gabexate.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Gabexate.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Gabexate.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Gabexate.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Gabexate.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Gabexate.Approved
SemapimodSemapimod may increase the anticoagulant activities of Gabexate.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Gabexate.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Gabexate.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Gabexate.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Gabexate.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Gabexate.Approved
SRT501SRT501 may increase the anticoagulant activities of Gabexate.Investigational
St. John's WortThe metabolism of Gabexate can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseStreptokinase may increase the anticoagulant activities of Gabexate.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Gabexate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Gabexate.Approved
SulindacSulindac may increase the anticoagulant activities of Gabexate.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Gabexate.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Gabexate.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Gabexate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Gabexate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Gabexate.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Gabexate.Approved, Investigational
TarenflurbilTarenflurbil may increase the anticoagulant activities of Gabexate.Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Gabexate is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Gabexate.Approved
TenidapTenidap may increase the anticoagulant activities of Gabexate.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Gabexate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Gabexate.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Gabexate.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Gabexate.Investigational
Testosterone cypionateThe therapeutic efficacy of Gabexate can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Gabexate can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Gabexate can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Gabexate.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Gabexate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Gabexate.Approved
TiboloneTibolone may increase the anticoagulant activities of Gabexate.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Gabexate.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Gabexate.Approved
TinoridineTinoridine may increase the anticoagulant activities of Gabexate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Gabexate.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Gabexate.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Gabexate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Gabexate.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Gabexate.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Gabexate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Gabexate is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Gabexate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Gabexate.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Gabexate.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Gabexate.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Gabexate.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Gabexate.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Gabexate.Approved
TriptolideTriptolide may increase the anticoagulant activities of Gabexate.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Gabexate.Approved
TroxerutinGabexate may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Gabexate.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Gabexate.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Gabexate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Gabexate.Approved
WarfarinWarfarin may increase the anticoagulant activities of Gabexate.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Gabexate.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Gabexate.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Gabexate.Approved
ZileutonZileuton may increase the anticoagulant activities of Gabexate.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Gabexate.Withdrawn
Food Interactions
Not Available

References

General References
  1. Yuksel M, Okajima K, Uchiba M, Okabe H: Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J Pharmacol Exp Ther. 2003 Apr;305(1):298-305. [PubMed:12649382]
  2. Menegatti E, Bolognesi M, Scalia S, Bortolotti F, Guarneri M, Ascenzi P: Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis. J Pharm Sci. 1986 Dec;75(12):1171-4. [PubMed:3104578]
  3. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]
  4. Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G: Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24. [PubMed:22911782]
  5. Xie LB, Zeng DY, Wang XD, Lin T, Li YP, Lu YP: Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats. Transplant Proc. 2014 Jan-Feb;46(1):40-5. doi: 10.1016/j.transproceed.2013.10.037. [PubMed:24507023]
  6. Kim SC, Yang HR: Clinical efficacy of gabexate mesilate for acute pancreatitis in children. Eur J Pediatr. 2013 Nov;172(11):1483-90. doi: 10.1007/s00431-013-2068-6. Epub 2013 Jun 29. [PubMed:23812506]
External Links
PubChem Compound
3447
PubChem Substance
347828997
ChemSpider
3329
BindingDB
50104435
ChEBI
93036
ChEMBL
CHEMBL87563
Wikipedia
Gabexate
MSDS
Download (79.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.109 mg/mLALOGPS
logP1.83ALOGPS
logP2.1ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)12.13ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area114.5 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity96.7 m3·mol-1ChemAxon
Polarizability35.47 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0119000000-c1086ad8b4cff4d62118

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Phenol esters / Phenoxy compounds / Benzoyl derivatives / Fatty acid esters / Dicarboxylic acids and derivatives / Guanidines / Carboxylic acid esters / Carboximidamides / Organopnictogen compounds / Organic oxides
show 3 more
Substituents
Benzoate ester / Phenol ester / Phenoxy compound / Benzoyl / Fatty acid ester / Dicarboxylic acid or derivatives / Fatty acyl / Carboxylic acid ester / Guanidine / Carboxylic acid derivative
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen an...
Gene Name
KLKB1
Uniprot ID
P03952
Uniprot Name
Plasma kallikrein
Molecular Weight
71369.205 Da
References
  1. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thrombospondin receptor activity
Specific Function
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
Gene Name
F2
Uniprot ID
P00734
Uniprot Name
Prothrombin
Molecular Weight
70036.295 Da
References
  1. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type peptidase activity
Specific Function
Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In...
Gene Name
PLG
Uniprot ID
P00747
Uniprot Name
Plasminogen
Molecular Weight
90568.415 Da
References
  1. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form aga...
Gene Name
PRSS1
Uniprot ID
P07477
Uniprot Name
Trypsin-1
Molecular Weight
26557.88 Da
References
  1. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activat...
Gene Name
C1S
Uniprot ID
P09871
Uniprot Name
Complement C1s subcomponent
Molecular Weight
76683.905 Da
References
  1. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Serine-type peptidase activity
Specific Function
C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.
Gene Name
C1R
Uniprot ID
P00736
Uniprot Name
Complement C1r subcomponent
Molecular Weight
80118.04 Da
References
  1. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase. Biochim Biophys Acta. 1977 Oct 13;484(2):417-22. [PubMed:143965]

Drug created on October 20, 2016 18:33 / Updated on December 01, 2017 17:35